2023
Update in the Treatment of the Complications of Cirrhosis
Abraldes J, Caraceni P, Ghabril M, Garcia-Tsao G. Update in the Treatment of the Complications of Cirrhosis. Clinical Gastroenterology And Hepatology 2023, 21: 2100-2109. PMID: 36972759, PMCID: PMC11097249, DOI: 10.1016/j.cgh.2023.03.019.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTransjugular intrahepatic portosystemic shuntVariceal hemorrhageHepatic encephalopathyPre-emptive transjugular intrahepatic portosystemic shuntsAcute variceal hemorrhageCombination of terlipressinAcute kidney injuryComplications of cirrhosisSecond-line treatmentSignificant portal hypertensionFirst-line treatmentLeast common causePrognosis of patientsOrnithine L-aspartatePresence of varicesIntrahepatic portosystemic shuntStandard of careQuality of lifeCyanoacrylate injectionHepatorenal syndromeUncomplicated ascitesKidney injuryPortal hypertensionRefractory ascitesAlbumin useMachine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
Noureddin M, Goodman Z, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Garcia‐Tsao G, Harrison S, Chalasani N. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. Alimentary Pharmacology & Therapeutics 2023, 57: 409-417. PMID: 36647687, PMCID: PMC10107331, DOI: 10.1111/apt.17363.Peer-Reviewed Original ResearchMeSH KeywordsFibrosisHumansHypertension, PortalLiverLiver CirrhosisNon-alcoholic Fatty Liver DiseasePortal PressureVaricose VeinsConceptsHepatic venous pressure gradientPresence of varicesEnd of treatmentValidation cohortLiver histology scoresPhase 2b trialPrimary efficacy endpointVenous pressure gradientDevelopment of varicesNonalcoholic steatohepatitis cirrhosisImportant histologic featuresImportant clinical relevanceHVPG changesEfficacy endpointHVPG measurementLiver histologyUpper endoscopyLiver biopsyLiver outcomesHistologic variablesNASH cirrhosisHistologic featuresHypertension assessmentCirrhosis (HALT-C) TrialClinical trials
2021
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases
Northup PG, Garcia‐Pagan J, Garcia‐Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 73: 366-413. PMID: 33219529, DOI: 10.1002/hep.31646.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2005
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis
Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL, Rosoff L, Garcia‐Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005, 42: 1184-1193. PMID: 16250039, DOI: 10.1002/hep.20897.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisUrsodeoxycholic acidVariceal bleedingBiliary cirrhosisTreatment failureSerum bilirubinHistological stagingCourse of PBCM2 body surface areaData Safety Monitoring BoardAMA-positive patientsReasons of futilityFailure of treatmentDevelopment of ascitesBody surface areaSafety monitoring boardEffect of methotrexateLiver transplantationPositive patientsMulticenter trialMedian periodMedian timeHistological progressionMonitoring boardDrug toxicity
1997
The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices
Escorsell A, Ferayorni L, Bosch J, Garcia-Pagan J, Garcia-Tsao G, Grace N, Rodes J, Groszmann R. The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997, 112: 2012-2016. PMID: 9178694, DOI: 10.1053/gast.1997.v112.pm9178694.Peer-Reviewed Original ResearchMeSH KeywordsAgedCalcium Channel BlockersFemaleHumansLiver CirrhosisMaleMiddle AgedPortal PressureTimololVaricose VeinsConceptsHepatic venous pressure gradientPortal pressure responseVenous pressure gradientCirrhotic patientsPortal pressurePortal hypertensionDevelopment of varicesSingle oral dosePressure responseSystemic hemodynamicsEsophageal varicesOral doseVaricesPatientsAbstractTextBeneficial effectsHypertensionTimololHgEarly stagesPressure gradientCirrhosisAIMSHemodynamicsDoseFurther evidence in favor of pharmacological portal pressure reduction in the prevention of variceal hemorrhage
García-Tsao G. Further evidence in favor of pharmacological portal pressure reduction in the prevention of variceal hemorrhage. Gastroenterology 1997, 112: 1770-1771. PMID: 9136864, DOI: 10.1016/s0016-5085(97)70067-2.Peer-Reviewed Original Research